| Year |
Citation |
Score |
| 2024 |
Menyhárt O, Fekete JT, Győrffy B. Resistance to Combined Anthracycline-Taxane Chemotherapy Is Associated with Altered Metabolism and Inflammation in Breast Carcinomas. International Journal of Molecular Sciences. 25. PMID 38256136 DOI: 10.3390/ijms25021063 |
0.335 |
|
| 2023 |
Menyhárt O, Fekete TJ, Győrffy B. [Increased activity of inflammation-related signaling pathways in anthracycline- paclitaxel resistant breast carcinomas]. Magyar Onkologia. 67: 203-212. PMID 37768118 |
0.356 |
|
| 2021 |
Menyhárt O, Fekete JT, Győrffy B. Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies. Carcinogenesis. 42: 804-813. PMID 33754151 DOI: 10.1093/carcin/bgab024 |
0.318 |
|
| 2020 |
Menyhárt O, Győrffy B. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. Cancer and Metastasis Reviews. 39: 211-233. PMID 31970590 DOI: 10.1007/S10555-020-09854-1 |
0.343 |
|
| 2019 |
Zhu C, Menyhart O, Győrffy B, He X. The prognostic association of SPAG5 gene expression in breast cancer patients with systematic therapy. Bmc Cancer. 19: 1-12. PMID 31690268 DOI: 10.1186/S12885-019-6260-6 |
0.42 |
|
| 2019 |
Menyhart O, Kakisaka T, Pongor LS, Uetake H, Goel A, Győrffy B. Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. Cancers. 11: 983. PMID 31337155 DOI: 10.3390/Cancers11070983 |
0.359 |
|
| 2019 |
Menyhárt O, Fekete JT, Győrffy B. Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan International Journal of Molecular Sciences. 20: 2750. PMID 31195594 DOI: 10.3390/Ijms20112750 |
0.406 |
|
| 2019 |
Menyhárt O, Győrffy B. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas. Annals of Clinical and Translational Neurology. 6: 990-1005. PMID 31139698 DOI: 10.1002/Acn3.762 |
0.347 |
|
| 2019 |
Menyhárt O, Giangaspero F, Győrffy B. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas. Journal of Hematology & Oncology. 12: 29. PMID 30876441 DOI: 10.1186/S13045-019-0712-Y |
0.308 |
|
| 2019 |
Menyhárt O, Pongor LS, Győrffy B. Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer. Frontiers in Pharmacology. 9: 1522. PMID 30670970 DOI: 10.3389/Fphar.2018.01522 |
0.305 |
|
| 2017 |
Menyhart O, Budczies J, Munkácsy G, Esteva FJ, Szabó A, Miquel TP, Győrffy B. DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. Oncotarget. 8: 77207-77218. PMID 29100381 DOI: 10.18632/Oncotarget.20430 |
0.423 |
|
| 2017 |
Ligeti B, Menyhart O, Petric I, Gyorffy B, Pongor S. Propagation on Molecular Interaction Networks: Prediction of Effective Drug Combinations and Biomarkers in Cancer Treatment. Current Pharmaceutical Design. 23: 5-28. PMID 27774896 DOI: 10.2174/1381612822666161021162727 |
0.303 |
|
| 2016 |
Menyhárt O, Harami-Papp H, Sukumar S, Schäfer R, Magnani L, de Barrios O, Győrffy B. Guidelines For The Selection of Functional Assays To Evaluate The Hallmarks of Cancer. Biochimica Et Biophysica Acta. PMID 27742530 DOI: 10.1016/J.Bbcan.2016.10.002 |
0.337 |
|
| 2016 |
Sadik H, Korangath P, Nguyen N, Győrffy B, Kumar R, Hedayati M, Teo WW, Park S, Panday H, Gonzalez Munoz T, Menyhart O, Shah N, Pandita RK, Chang JC, DeWeese TL, et al. HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells. Cancer Research. PMID 27302171 DOI: 10.1158/0008-5472.Can-16-0774 |
0.347 |
|
| 2016 |
Györffy B, Munkacsy G, Esteva F, Miquel T, Menyhart O. Abstract P5-08-22: DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-08-22 |
0.424 |
|
| 2015 |
Menyhárt O, Santarpia L, Győrffy B. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. Current Cancer Drug Targets. 15: 665-683. PMID 26452383 DOI: 10.2174/156800961508151001101742 |
0.425 |
|
| 2015 |
Munkácsy G, Szász MA, Menyhárt O. Gene expression-based prognostic and predictive tools in breast cancer. Breast Cancer (Tokyo, Japan). 22: 245-52. PMID 25874688 DOI: 10.1007/S12282-015-0594-Y |
0.4 |
|
| Show low-probability matches. |